NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology
Ana I. Rojo,
Marta Pajares,
Patricia Rada,
Angel Nuñez,
Alejo J. Nevado-Holgado,
Richard Killik,
Fred Van Leuven,
Elena Ribe,
Simon Lovestone,
Masayuki Yamamoto,
Antonio Cuadrado
Affiliations
Ana I. Rojo
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII. Instituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC. Instituto de Investigación Sanitaria La Paz (IdiPaz), and Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain
Marta Pajares
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII. Instituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC. Instituto de Investigación Sanitaria La Paz (IdiPaz), and Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain
Patricia Rada
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIII, Madrid, Spain. Instituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC. Instituto de Investigación Sanitaria La Paz (IdiPaz); and Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain
Angel Nuñez
Department of Anatomy, Histology and Neuroscience, Autonomous University of Madrid, Madrid, Spain
Alejo J. Nevado-Holgado
Department of Psychiatry, Warneford Hospital, University of Oxford, OX3 7JX UK
Richard Killik
King's College London, Institute of Psychiatry, Psychology and Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Camberwell, London, UK
Fred Van Leuven
Experimental Genetics Group-LEGTEGG, Department of Human Genetics, KU Leuven, Leuven, Belgium
Elena Ribe
Department of Psychiatry, Warneford Hospital, University of Oxford, OX3 7JX UK
Simon Lovestone
Department of Psychiatry, Warneford Hospital, University of Oxford, OX3 7JX UK
Masayuki Yamamoto
Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan
Antonio Cuadrado
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII. Instituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC. Instituto de Investigación Sanitaria La Paz (IdiPaz), and Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain
Failure to translate successful neuroprotective preclinical data to a clinical setting in Alzheimer's disease (AD) indicates that amyloidopathy and tauopathy alone provide an incomplete view of disease. We have tested here the relevance of additional homeostatic deviations that result from loss of activity of transcription factor NRF2, a crucial regulator of multiple stress responses whose activity declines with ageing. A transcriptomic analysis demonstrated that NRF2-KO mouse brains reproduce 7 and 10 of the most dysregulated pathways of human ageing and AD brains, respectively. Then, we generated a mouse that combines amyloidopathy and tauopathy with either wild type (AT-NRF2-WT) or NRF2-deficiency (AT-NRF2-KO). AT-NRF2-KO brains presented increased markers of oxidative stress and neuroinflammation as well as higher levels of insoluble phosphorylated-TAU and Aβ*56 compared to AT-NRF2-WT mice. Young adult AT-NRF2-KO mice exhibited deficits in spatial learning and memory and reduced long term potentiation in the perforant pathway. This study demonstrates the relevance of normal homeostatic responses that decline with ageing, such as NRF2 activity, in the protection against proteotoxic, inflammatory and oxidative stress and provide a new strategy to fight AD.